MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (Nasdaq:SABS), ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
TipRanks on MSN
SAB Biotherapeutics launches new $75 million ATM program
SAB Biotherapeutics ( ($SABS) ) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback